TickerTalks
Browse all tickers →
TickerTalks›$ONCY
ONONCY

Oncolytics Biotech Inc.

$ONCY·$63M·Biotechnology·Healthcare
$0.54-8.6%YTD-34.3%1Y-55.9%
Price updated 47m ago·X counts updated 4d ago
ONONCY
$ONCYOncolytics Biotech Inc.
$0.54-8.63%67 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $ONCY on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

67X posts · last 7 days
Sep 21Oct 4
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $ONCY's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data5 posts analyzed · as of 2026-09-08

Oncolytics got FDA feedback supporting a highly efficient path to transition REO 033 from randomized Part A directly into pivotal Part B, with alignment on response rate for accelerated approval and PFS for full approval. CEO Jared Kelly framed the guidance as thoughtful and clear.

Read what X is saying about $ONCY

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $ONCY — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Oncolytics got FDA feedback supporting a direct REO 033 Part A to Part B transition — accelerated approval on response rate.

Oncolytics Biotech is a clinical-stage immuno-oncology company — pelareorep is the lead candidate, now REO 033 moving toward pivotal Phase 2b in solid tumors. The business is pre-revenue and the latest FDA interaction was constructive.

  • The business is pre-revenue: PS reads as zero, operating margin uninformative, PE -3.2 — standard clinical-stage biotech P&L where the thesis is regulatory and clinical cadence.
  • The regulatory signal is specific: FDA feedback supports a highly efficient transition of REO 033 from randomized Part A directly into pivotal Part B, with alignment on response rate for accelerated approval and PFS for full approval — a dated regulatory milestone that saves a trial step.
  • 52-week range position is 1.3% at $0.64 with volume at 71% of average — near the absolute floor on quiet volume, which is capitulation territory for a late-stage biotech with a defined regulatory path.

Nov 11 Q3 is the gate — any additional REO 033 enrollment milestones plus cash runway confirmation extend the stock off the floor. A dilutive raise or any clinical setback and the stock stays at the lows.

Agrees with X sentimentThe thread has substantive drivers — the specific FDA feedback supporting Part A to Part B transition, response rate for accelerated approval, PFS for full approval, CEO Jared Kelly's thoughtful-and-clear framing — all grounded in actual regulatory interaction.

What to watch: Nov 11 Q3 — REO 033 enrollment, cash runway, any FDA correspondence updates, and pipeline progression. A dilutive raise is the hard invalidator.

On the calendar: 2026-11-11 — Q3 earnings

Read the AI verdict on $ONCY

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Oncolytics Biotech is testing its oncolytic reovirus (pelareorep) as a combination cancer immunotherapy in multiple clinical trials.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $ONCY.

Biotechnology · Healthcare

No material change from last week — mRNA oncology platform remains the structural driver.

What this means for $ONCY

Neutral — Oncolytics Biotech is testing its oncolytic reovirus (pelareorep) as a combination cancer immunotherapy in multiple clinical trials.

Top industry ETF

$IBBiShares Biotechnology ETF
+19.7%YTD
+34.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-3.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-14.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-21.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
10.2%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-0.08$-0.05-48.7%
Q1 2026May 14, 2026$-0.08$-0.05-60.0%
Q4 2025Mar 30, 2026$-0.01$-0.06+83.1%
Q3 2025Nov 12, 2025$-0.10$-0.12+16.7%
Next earningsWed, Nov 11·consensus EPS $-0.07

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.08$-5.3M
Q1 FY26$0———$-0.11$-7.3M
Q4 FY25$0———$-0.01$-6.7M
Q3 FY25$0———$-0.14$-4.6M

Forward consensus

5-year forecast · up to 5 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.2M$1.2M – $1.2M-$0.34-$0.35 – -$0.325
FY27$595K$595K – $595K-$0.26-$0.28 – -$0.252
FY28$17.1M$17.1M – $17.1M-$0.26-$0.41 – -$0.033
FY29$87.7M$87.7M – $87.7M-$0.26-$0.26 – -$0.261
FY30$179.1M$179.1M – $179.1M-$0.14-$0.14 – -$0.142

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.2%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-22.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-34.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 116.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.165-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KListing / delisting noticeJul 248-K — Item 3.01: Listing / delisting notice
8-KMaterial eventJul 88-K — Item 4.01
3New insider — initial holdingsJun 33
3New insider — initial holdingsJun 33
8-KOfficer or director changeJun 28-K — Item 5.02: Officer or director change · Item 8.01: Other event
+ 15 other (11 routine 8-Ks · 2 proxys · 2 10-Qs) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapyglobenewswire.com·10d agoOncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Studyglobenewswire.com·11d agoOncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancerglobenewswire.com·29d agoOncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancerglobenewswire.com·52d agoOncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancerglobenewswire.com·81d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$KOD$MRNA$IOVA$ARCT$IBRX$VKTX$NWBO$QURE
Voices on X · last 7 days

No standout posts about $ONCY on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport